Low-molecular contrast agent dynamic contrast-enhanced (DCE)-MRI and diffusion-weighted (DW)-MRI in early assessment of bevacizumab treatment in breast cancer xenografts (Q39116695)

From Wikidata

Jump to navigation Jump to search

scientific article published on 21 March 2013

Language	Label	Description	Also known as
English	Low-molecular contrast agent dynamic contrast-enhanced (DCE)-MRI and diffusion-weighted (DW)-MRI in early assessment of bevacizumab treatment in breast cancer xenografts	scientific article published on 21 March 2013

Statements

scholarly article

1 reference

Europe PubMed Central

9 September 2017

Low-molecular contrast agent dynamic contrast-enhanced (DCE)-MRI and diffusion-weighted (DW)-MRI in early assessment of bevacizumab treatment in breast cancer xenografts (English)

1 reference

Europe PubMed Central

9 September 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

7

object named as

Lars A Akslen

1 reference

Europe PubMed Central

9 September 2017

Ingrid Susann Gribbestad

8

object named as

Ingrid S Gribbestad

1 reference

Europe PubMed Central

9 September 2017

Gunhild M. Mælandsmo

6

object named as

Gunhild M Mælandsmo

1 reference

Europe PubMed Central

9 September 2017

Olav Engebraaten

5

object named as

Olav Engebraaten

1 reference

Europe PubMed Central

9 September 2017

4

object named as

Anna Bofin

1 reference

Europe PubMed Central

9 September 2017

Evita Maria Lindholm

3

object named as

Evita M Lindholm

1 reference

Europe PubMed Central

9 September 2017

Siver Andreas Moestue

1

object named as

Siver A Moestue

1 reference

Europe PubMed Central

9 September 2017

2

object named as

Else M Huuse

1 reference

Europe PubMed Central

9 September 2017

publication date

21 March 2013

1 reference

Europe PubMed Central

9 September 2017

Journal of Magnetic Resonance Imaging

1 reference

Europe PubMed Central

9 September 2017

38

1 reference

Europe PubMed Central

9 September 2017

5

1 reference

Europe PubMed Central

9 September 2017

1043-1053

1 reference

Europe PubMed Central

9 September 2017

Isolation of a tumor factor responsible for angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24079

21 January 2018

Anticancer strategies involving the vasculature

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24079

21 January 2018

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24079

21 January 2018

Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24079

21 January 2018

Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24079

21 January 2018

Potentiation of cyclophosphamide chemotherapy using the anti-angiogenic drug thalidomide: importance of optimal scheduling to exploit the 'normalization' window of the tumor vasculature

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24079

21 January 2018

Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11.

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24079

21 January 2018

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24079

21 January 2018

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24079

21 January 2018

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24079

21 January 2018

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24079

21 January 2018

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24079

21 January 2018

Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24079

21 January 2018

Dynamic contrast-enhanced MRI in the diagnosis and management of breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24079

21 January 2018

Predicting and monitoring cancer treatment response with diffusion-weighted MRI.

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24079

21 January 2018

MRI monitoring of Avastin antiangiogenesis therapy using B22956/1, a new blood pool contrast agent, in an experimental model of human cancer

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24079

21 January 2018

Vascular permeability during antiangiogenesis treatment: MR imaging assay results as biomarker for subsequent tumor growth in rats

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24079

21 January 2018

Tumor microvascular changes in antiangiogenic treatment: assessment by magnetic resonance contrast media of different molecular weights.

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24079

21 January 2018

Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations.

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24079

21 January 2018

In vivo MRI and histopathological assessment of tumor microenvironment in luminal-like and basal-like breast cancer xenografts

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24079

21 January 2018

Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24079

21 January 2018

Effect of antiangiogenic therapy on tumor growth, vasculature and kinase activity in basal- and luminal-like breast cancer xenografts

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24079

21 January 2018

Assessment of early docetaxel response in an experimental model of human breast cancer using DCE-MRI, ex vivo HR MAS, and in vivo 1H MRS.

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24079

21 January 2018

Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols.

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24079

21 January 2018

Phosphohistone H3 expression has much stronger prognostic value than classical prognosticators in invasive lymph node-negative breast cancer patients less than 55 years of age.

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24079

21 January 2018

Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24079

21 January 2018

Vascular proliferation is increased in basal-like breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24079

21 January 2018

Noninvasive evaluation of antiangiogenic effect in a mouse tumor model by DCE-MRI with Gd-DTPA cystamine copolymers

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24079

21 January 2018

Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24079

21 January 2018

Identifiers

10.1002/JMRI.24079

1 reference

Europe PubMed Central

9 September 2017

1 reference

Europe PubMed Central

9 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39116695&oldid=1858982950"